Antithrombotic drugs for secondary stroke prophylaxis

Pharmacotherapy

Volumn 21, Issue 4, 2001, Pages 452-463

  Pettigrew, L C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOCYTOPENIC PURPURA;

EID: 0035066686     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.5.452.34498     Document Type: Review

References (63)

1. Deaths: Final data for 1996
2. The greater Cincinnati/northern Kentucky stroke study: Preliminary first-ever and total incidence rates of stroke among blacks
3. Cost of stroke
4. Lifetime cost of stroke in the United States
5. Tissue plasminogen activator for acute ischemic stroke
6. Antithrombotics and thrombolytic therapy for ischemic stroke
7. Guidelines for carotid endarterectomy. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association
8. Pharmacology of current and future antithrombotic therapies
9. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
10. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1α excretion in healthy subjects
11. Antiplatelet therapy
12. Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects
13. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses
14. Randomised trial of prophylactic daily aspirin in British male doctors
15. Final report on the aspirin component of the ongoing physicians' health study
16. Controlled trial of aspirin in cerebral ischemia
17. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
18. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions: The results of a double-blind trial
19. Prevention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires: Résultats d'un essai thérapeutique contrôlé de 3 ans
20. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
21. High-dose acetylsalicylic acid after cerebral infarction: A Swedish cooperative study
22. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
23. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results
24. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
25. Acetylsalicylic acid in prevention of stroke in patients with reversible cerebral ischemic attacks: A Danish cooperative study
26. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
27. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
28. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
29. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia
30. A metaregression analysis of the dose-response effect of aspirin on stroke
31. Low-dose aspirin and stroke. "It ain't necessarily so"
32. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products
33. Clopidogrel, a novel antiplatelet and antithrombotic agent
34. The antiplatelet effects of ticlopidine and clopidogrel
35. 3H]-2-methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine
36. Clopidogrel
37. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine aspirin stroke study group
38. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke
39. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
40. The role of ticlopidine in prevention of ischemic stroke: A benefit-risk assessment
41. Prevention of stroke with ticlopidine: Who benefits most? TASS baseline and angiographic data subgroup
42. Ticlopidine, trials, and torture
43. Adverse haematological effects of ticlopidine. Prevention, recognition and management
44. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases
45. Benefit of clopidogrel in patients with evidence of cerebrovascular disease
46. Thrombotic thrombocytopenic purpura associated with clopidogrel
47. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin
48. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: Influence of salicylate and dipyridamole treatment
49. A rationale for targeting antithrombotic therapy at the vessel wall: Improved antithrombotic effect and decreased risk of bleeding
50. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo
51. Dipyridamole plus aspirin in cerebrovascular disease
52. European stroke prevention study
53. Dipyridamole trials in stroke prevention
54. European stroke prevention study 2. Efficacy and safety data
55. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man
56. Rapid development of tolerance to dipyridamole-associated headaches
57. Persantine aspirin trial in cerebral ischemia. II. End point results
58. Comparison of ticlopidine and aspirin for the prevention of stroke
59. Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin
60. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole
61. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack
62. Antithrombotic and thrombolytic therapy for ischemic stroke